Amgen
Executive Summary
Manufactured "over 500,000 doses of recombinant DNA products" in fiscal 1987 (year ended March 31) at its GMP facility, a more than tenfold increase over the previous year, firm's most recent annual report notes. Company is doubling existing capacity with a 20,000 sq. ft. mammalian cell culture facility at its Thousand Oaks, California site, scheduled for completion in the current fiscal year. Firm also plans a 1988 product license application filing for its erythropoietin product EPO.
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.